Building data and intelligence capabilities to provide evidence of impact for the profession

In association with pharmaphorum, Tag discusses what pharmaceutical marketers can to do stay ahead of the evolving customer journey.

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder affecting some 40,000 individuals in Europe at any time, causing 10,000 deaths each year. As with other age-related neurodegenerative diseases, the drug development field is littered with inconclusive or negative trials. Modifying Immune Response and Outcomes in ALS (MIROCALS) is an international European Union H2020-funded trial of low-dose interleukin-2 in motor neuron disease (MND)/ALS. It aims to break this impasse in the development of disease-modifying agents through novel trial design, incident (early post-diagnosis) recruitment, integration of biomarkers/transcriptomics and cohort stratification. Join this webinar to hear about an overview of the study in addition to a discussion of the challenges both anticipated and unanticipated in recruiting participants recently diagnosed with a rare, rapidly disabling and ultimately life-limiting condition.

The pandemic was a unique time in our industry where there was a perfect storm of need, money, collaboration, and trial patients all available in abundance.  There was an atmosphere of all hands, and resources, on deck in the race to a COVID-19 vaccine.

Competency-based medical education (CBME) requires a vigorous and multidimensional assessment system. In order to successfully implement CBME, assessment processes must be continuous and frequent.